Starpharma (Australia)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 13 papers

  • Research Article

Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

  • Jan 20, 2024
  • Journal of Clinical Oncology
  • David James Pinato +12
  • Open Access
  • Research Article
  • Citations8

In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate

  • Mar 31, 2023
  • International Journal of Pharmaceutics
  • Silvia Sonzini +14
  • Research Article
  • Citations4

Indium-labelled autologous platelet sequestration studies predict response to splenectomy in immune thrombocytopenia: an Australian experience.

  • May 31, 2022
  • Internal Medicine Journal
  • Sumita Ratnasingam +6
  • Open Access
  • Research Article
  • Citations4

Transferring and extrapolating estimates of cost-effectiveness for water quality outcomes: Challenges and lessons from the Great Barrier Reef

  • Sep 08, 2021
  • Marine Pollution Bulletin
  • Megan Star +3
  • Open Access
  • Research Article
  • Citations1

Letter to the Editor: Recommendations for Implementing Hepatitis C Virus Care in Homeless Shelters: The Stakeholder Perspective

  • Oct 16, 2020
  • Hepatology Communications
  • Brendan Harney +6
  • Research Article
  • Citations2

Abstract 1715: Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon cancer xenograft models

  • Aug 13, 2020
  • Cancer Research
  • Brian D Kelly +13
  • Research Article
  • Citations121

Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent

  • Jun 26, 2013
  • Molecular Pharmaceutics
  • Gemma M Ryan +5
  • Open Access
  • Research Article
  • Citations129

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

  • May 15, 2011
  • AIDS
  • Ian Mcgowan +9
  • Open Access
  • PDF
  • Research Article
  • Citations79

A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days

  • Jan 20, 2011
  • PLoS ONE
  • Craig R Cohen +6
  • Open Access
  • Research Article
  • Citations103

Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A Dose Ranging, Phase I Study

  • Feb 01, 2010
  • Sexually Transmitted Diseases
  • John O'loughlin +5
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.